Navigation Links
Merrimack Pharmaceuticals Announces Results From A Phase 2 Study Of MM-121 (SAR256212) In Combination With Paclitaxel In Patients With Platinum-Resistant Or Refractory Advanced Ovarian Cancers
Date:10/30/2013

CAMBRIDGE, Mass., Oct. 30, 2013 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced results of a global, Phase 2, open-label, randomized study of MM-121 in combination with paclitaxel versus paclitaxel alone in patients with platinum-resistant or platinum-refractory advanced ovarian cancers.

This study did not meet the primary endpoint of progression free survival in the overall population.  The hazard ratio (HR) for progression free survival (PFS) was 1.0 [95% CI 0.74 - 1.4].

Ongoing analysis of a pre-specified set of biomarkers mechanistically linked to ErbB3 signaling identified a potential subpopulation of patients benefiting from MM-121 treatment in combination with paclitaxel. When using a combination of two biomarkers, the hazard ratio for PFS was 0.37 [95% CI 0.2 - 0.8] in the 34% of patients who were biomarker positive. The hazard ratio for PFS in the biomarker negative population was 1.54 [95% CI 1.0 - 2.4].

An overall increase in all grades of gastrointestinal toxicities, including diarrhea (73.6% vs. 42.5%), vomiting (31.4% vs. 18.8%) and other mucosal toxicities such as rhinitis (7.1% vs. 1.3%), epistaxis (23.6% vs. 17.5%), stomatitis (22.1% vs. 10.0%) and mucosal inflammation (22.1% vs. 1.3%), were observed in the combination as compared to paclitaxel alone, the majority of which were mild to moderate in severity. An increase in the pulmonary embolism rate was observed with the combination of MM-121 and paclitaxel (5.0% vs. 1.2%). No enhancement of paclitaxel-related peripheral neuropathy was reported with the combination.

"This unique study design lays the groundwork for future translational studies in ovarian cancer. The rapid enrollment into this study was a testament to the commitment of patients and physicians to advance our knowledge and improve upon available therapies i
'/>"/>

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Earnings Releases, Investment Plans, Commencement of Clinical Trials, and FDA Applications Brighten Outlook - Research Report on Bard, Centene, Exact Sciences, Ironwood, and Merrimack
2. Merrimack Pharmaceuticals Phase 1 Research Supports MM-121 Potential For Investigation As Combination With Chemotherapy In Patients With Advanced Solid Tumors
3. Merrimack Pharmaceuticals Preclinical Research Shows MM-111 Restores Sensitivity To Chemotherapy And HER2-targeted Treatment In Gastric Cancer Model
4. Merrimack Pharmaceuticals Preclinical Research Shows MM-121 Restores Sensitivity to Anti-Estrogen Therapy and Delays Onset of Treatment Resistance in ER-Positive Breast Cancer Model
5. Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor
6. Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer
7. Anthera Pharmaceuticals Reports 2013 Third Quarter Financial Results, Clinical and Regulatory Update
8. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2013 Financial Results On November 5, 2013
9. Cumberland Pharmaceuticals To Announce Third Quarter 2013 Financial Results On November 5, 2013
10. Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2013 Year End Financial Information
11. Lumena Pharmaceuticals Initiates the CLARITY Phase II Study of LUM001 in Patients with Primary Biliary Cirrhosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014 Oramed Pharmaceuticals ... clinical-stage pharmaceutical company focused on the development of ... clinical results from its Phase IIa clinical trial ... to treat type 1 diabetes. The trial was conducted ... under a U.S. Food and Drug Administration (FDA) ...
(Date:10/22/2014)... UNION CITY, Calif., Oct. 21, 2014 Abaxis, ... company manufacturing point-of-care blood analysis systems, today reported financial ... 2014. Second quarter overview: , Revenues ... quarter. , Diluted EPS of $0.24, up 33% ... , Service revenues from Abaxis Veterinary Reference Laboratories ...
(Date:10/22/2014)... , Oct. 22, 2014 InVivo Therapeutics Holdings ... is revolutionizing spinal cord injury (SCI) treatment ... shown to outperform in tissue regrowth in the spinal ... Made from an FDA approved polymer, the scaffold ultimately ... harmless to the human body. NVIV has recently attracted ...
Breaking Medicine Technology:Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3
... CITY, June 23, 2011 PD-Rx Pharmaceuticals, Inc., ... the purchase of the Washington EMR, an electronic ... Washington EMR is the premier quality, low-cost ... The intuitive interface allows the physician and assistants ...
... SAN DIEGO, June 23, 2011 BioSurplus today announced ... of instruments worth over $10 million will be auctioned ... The first auction will have choice laboratory equipment ... HPLCs and Mass Specs, Molecular Devices Spectramax M5 plate ...
Cached Medicine Technology:PD-Rx Pharmaceuticals Acquires Wilson Medical's EMR 2BioSurplus Selected to Auction $10 Million in Lab Equipment 2
(Date:10/22/2014)... (PRWEB) October 22, 2014 ... staffing company, is happy to announce that our ... to Staffing Industry Analysts’ Staffing 100 for 2014. ... the “100 most influential people in the staffing ... Medical Solutions, the 13th-largest healthcare staffing company in ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... in Dallas. But, mental health specialists say overblown fear is ... Obama on Friday appointed an Ebola "czar" to oversee the ... nurses who cared for a Liberian man who died of ... the U.S. cases are miniscule in the context of the ...
(Date:10/22/2014)... The Louis W. Sullivan ... to distribute health information technology innovation to transform ... the development of six key guiding principles of ... healthcare. These are an expansion of the Institute ... that is respectful of and responsive to individual ...
(Date:10/22/2014)... Pass, OR (PRWEB) October 22, 2014 ... Southern California’s fresh water supply runs dangerously low, Southern ... change. Southern Oregon’s rivers, despite the lowest mountain snow ... even in late summer and early autumn.* That was ... authors of the new book “Hiking Southern Oregon,” during ...
(Date:10/22/2014)... Your Body’s Way , In a world where a multi-billion-dollar ... can be difficult to choose the right weight loss method. ... it the healthy way? Set aside the fads and resist ... regularly, and choose foods with the most nutritional benefits. ... exercise more and eat less. Despite the number of advertisements ...
Breaking Medicine News(10 mins):Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 3Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2
... President Barack Obama is expected to support removing federal ... and is looking to Congress to introduce legislation to ... Bush administration cut off federal research support for hESC ... Jonathan Slack, director of the University of ...
... Educational Initiative are AnnouncedPITTSBURGH, Jan. 29 ... patient reported outcomes (ePRO) solutions and services ... registration for ePROficiency(TM) 2009 -- its annual ... professionals can visit http://www.invivodata.com/epro2009 to ...
... researchers have been selected as additions to the ... of Evidence-based HIV Prevention Interventions. , The UCSF ... Healthy Living Projectcomprise two of the eight added ... effective HIV prevention programs recommended by the CDC ...
... of a study, presented at The Endocrine Society,s 90th ... high in carbohydrates and protein followed by a low-carb, ... in keeping dieters on track with their weight loss ... Clinicas, Caracas, Venezuela, along with scientists from Virginia ...
... American Journal of Public Health Article Reveals Intensive ... Goals of Welfare ReformNEW YORK, Jan. 29 ... welfare that treats substance abuse and addiction as ... and employment than current approaches that focus on ...
... Ill., Jan. 29 Z Trim Holdings, Inc.,(OTC ... World Technology Ingredients (WTI), a specialty ingredients company ... Z Trim ingredients will be,represented to the meat ... Based in Jefferson, Georgia, where they maintain a ...
Cached Medicine News:Health News:University of Minnesota's Internationally Recognized Stem Cell Experts Available for Interviews on What Lifting the Federal Funding Restrictions Will Mean to Stem Cell Research and to Patients Who Stand to Benefit 2Health News:invivodata Opens Registration for Annual Patient Reported Outcomes Conference 2Health News:invivodata Opens Registration for Annual Patient Reported Outcomes Conference 3Health News:CDC recognizes UCSF's research as critical to HIV prevention 2Health News:CDC recognizes UCSF's research as critical to HIV prevention 3Health News:New Study: Protein in the Morning Helps Dieters Stay on Track and Keep Weight Off 2Health News:CASA* Evaluation of Welfare Demonstration Program in New Jersey Finds Effective Approach to Addiction Recovery and Employment 2Health News:CASA* Evaluation of Welfare Demonstration Program in New Jersey Finds Effective Approach to Addiction Recovery and Employment 3Health News:CASA* Evaluation of Welfare Demonstration Program in New Jersey Finds Effective Approach to Addiction Recovery and Employment 4Health News:CASA* Evaluation of Welfare Demonstration Program in New Jersey Finds Effective Approach to Addiction Recovery and Employment 5Health News:Z Trim to Be Distributed to Meat and Poultry Industries by World Technology Ingredients 2Health News:Z Trim to Be Distributed to Meat and Poultry Industries by World Technology Ingredients 3Health News:Z Trim to Be Distributed to Meat and Poultry Industries by World Technology Ingredients 4
... Many special order products are offered as ... long lengths. The modular instruments may be ... options such as ratchets, insulation and flush ... Mediflex stock. Customer specifications may affect delivery ...
... order products are offered as 1-piece or ... The modular instruments may be customized with ... as ratchets, insulation and flush ports. Many ... Customer specifications may affect delivery times. ...
... offered as 1-piece or modular, in regular ... may be customized with handles of choice ... and flush ports. Many standard patterns are ... affect delivery times. , Please Note: ...
... order products are offered as 1-piece or ... The modular instruments may be customized with ... as ratchets, insulation and flush ports. Many ... Customer specifications may affect delivery times. ...
Medicine Products: